Sharon Mates - 24 Apr 2024 Form 4 Insider Report for Intra-Cellular Therapies, Inc. (ITCI)

Role
Chairman and CEO, Director
Signature
/s/ Lawrence J. Hineline, Attorney-in-fact
Issuer symbol
ITCI
Transactions as of
24 Apr 2024
Net transactions value
+$345,618
Form type
4
Filing time
25 Apr 2024, 17:08:34 UTC
Previous filing
11 Mar 2024
Next filing
23 Aug 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ITCI Common Stock Options Exercise $145,637 +8,638 +0.82% $16.86 1,058,947 24 Apr 2024 Direct
transaction ITCI Common Stock Options Exercise $199,982 +11,382 +1.1% $17.57 1,070,329 24 Apr 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ITCI Stock Option (right to buy) Options Exercise $0 -8,638 -100% $0.000000* 0 24 Apr 2024 Common Stock 8,638 $16.86 Direct F1
transaction ITCI Stock Option (right to buy) Options Exercise $0 -11,382 -5% $0.000000 216,998 24 Apr 2024 Common Stock 11,382 $17.57 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option was granted on June 30, 2014 with an exercise price of $16.86 per share and will expire on June 30, 2024. All shares underlying this option have vested.
F2 This option was granted on January 2, 2015 with an exercise price of $17.57 per share and will expire on January 2, 2025. All shares underlying this option have vested.